Company Updates - The company announced a research and development collaboration and licensing agreement with AstraZeneca for eight innovative long-acting peptide drug projects, including SYH2082 and three preclinical molecules, with an additional four projects under collaboration [1] - AstraZeneca will pay a total of $1.2 billion in upfront payments and up to $3.5 billion in development and sales milestone payments, with a subsidiary entitled to receive 35% of the upfront payment and subsequent milestone payments and royalties [1] Industry Insights - The collaboration marks a significant milestone for Chinese innovative drug licensing abroad, as multinational corporations (MNCs) are betting on long-acting peptide drugs to compete in the weight loss and metabolic market [1] - The company’s SYH2082 is a long-acting GLP1R/GIP agonist progressing to Phase I clinical trials, with expectations for more favorable efficacy and safety data [1] Revenue Generation - The company has achieved external licensing agreements in 2025, including $120 million for oral small molecule GLP-1, $110 million for the AstraZeneca collaboration, and $15 million for other projects, indicating a potential for regular income from licensing [2] - The company has a pipeline of innovative assets, including EGFR ADC/SiRNA series, which are expected to lead to further licensing agreements and milestone revenue recognition [2] Profit Forecast and Valuation - The profit forecast for 2025 and 2026 is maintained at 4.76 billion yuan and 5.35 billion yuan, with an introduction of a 2027 forecast of 5.70 billion yuan [2] - The current stock price corresponds to a price-to-earnings ratio of 18.7 and 17.1 times for 2026 and 2027, respectively, with a target price adjustment of 9.1% to HKD 12.00, implying a 25% upside potential [2]
石药集团(01093.HK)：与阿斯利康达成重磅合作 创新药出海再获里程碑式突破